Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Plasma amyloid β42 peptide (Aβ42) levels are significantly elevated in all genetic forms of early‐onset Alzheimer’s disease caused by familial Alzheimer’s disease mutations or Down’s syndrome. Moreover, recent studies have determined that both plasma Aβ42 and Aβ40 levels are significantly elevated in late‐onset Alzheimer’s disease (LOAD) patients, their cognitively normal first‐degree relatives, and members of typical LOAD families when compared to appropriate controls. To determine the magnitude of the genetic component affecting plasma Aβ levels, we estimated the heritability of plasma Aβ42 and Aβ40 in 15 extended, multigenerational LOAD pedigrees, using a variance components method. Heritability estimates as high as 73 and 54% were found for plasma Aβ42 and Aβ40 levels, respectively. Inclusion of the ApoE ϵ4 dosage as a covariate was not found to have a significant effect on the heritability of these traits. These results suggest that genetic determinants other than ApoE account for a very substantial percentage of the phenotypic variance in plasma Aβ levels. The high heritability and the significant elevation of these traits in LOAD pedigrees suggest that at least some of the genetic determinants of plasma Aβ levels may lead to elevated Aβ and LOAD in these families. Thus, we suggest that plasma Aβ levels are quantitative traits that may be excellent surrogate markers for use in linkage analysis to identify loci that are important in typical LOAD. Genet. Epidemiol. 21:19–30, 2001. © 2001 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“…in cells transfected with mutant PS1, PS2, and APP genes, transgenic mouse models of AD, and plasma and CSF from early onset AD cases and their first-degree relatives [Citron et al., 1992; Suzuki et al., 1994; Scheuner et al., 1996; Borchelt et al., 1996; Duff et al., 1996; Eckman et al., 1997].”
BackgroundSelf-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“…in cells transfected with mutant PS1, PS2, and APP genes, transgenic mouse models of AD, and plasma and CSF from early onset AD cases and their first-degree relatives [Citron et al., 1992; Suzuki et al., 1994; Scheuner et al., 1996; Borchelt et al., 1996; Duff et al., 1996; Eckman et al., 1997].”
BackgroundBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Self-citationSuzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Self-citationAmyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 2×
“All known autosomal dominant genetic forms of Alzheimer’s disease (AD) are invariably associated with an elevation in the levels of A β42 peptide, which is sometimes also accompanied by an increase in A β40 levels [Hardy, 1997; Hutton and Hardy, 1997].”
BackgroundKawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053
Self-citationApoE-4 and Age at Onset of Alzheimer's Disease: The NIMH Genetics Initiative
Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C. P., Harrell, L. E., Perry, R. T., Bassett, S. S., Chase, G., Meyers, D., et al. (1997) · Neurology · doi:10.1212/wnl.48.1.139 · Cited by 479 · cited 1×
“This person also had an ε4/ε4 genotype [Blacker et al., 1997].”
BackgroundAPOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397 · cited 1×
“The attributable risk of the ApoE ε4 allele for Alzheimer’s disease is as high as 40–70% [Tol et al., 1999; Breitner et al., 1999].”
BackgroundMyers, R. H., Schaefer, E. J., Wilson, P. W. F., D'Agostino, R., Ordovas, J. M., Espino, A., Au, R., White, R. F., Knoefel, J. E., Cobb, J. L., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.673 · Cited by 346 · cited 1×
“However, individuals without the ApoE ε4 allele are still at risk for AD, and as many as 50% of those who are ApoE ε4 homozygotes may reach old age and still not develop AD, indicating that this genetic factor is neither necessary nor sufficient for the development of AD [Myers et al., 1996].”
BackgroundA New Pathogenic Mutation in the APP Gene (I716V) Increases the Relative Proportion of A 42(43)
Eckman, C. B., Mehta, N. D., Crook, R., Perez-tur, J., Prihar, G., Pfeiffer, E., Graff-Radford, N., Hinder, P., Yager, D., Zenk, B., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2087 · Cited by 236
Self-citationPericak-Vance, M. A. (1997) · JAMA · doi:10.1001/jama.1997.03550150041033 · Cited by 206
Cited by
Graff-Radford, N. R., Crook, J. E., Lucas, J., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 441
Self-citationPlasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Functions and dysfunctions of nitric oxide in brain
Picón-Pagès, P., Garcia-Buendia, J., & Muñoz, F. J. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.007 · Cited by 347
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 257
Alzheimer disease therapy: Can the amyloid cascade be halted?
Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17527 · Cited by 164
Metadata
- Authors
- Ertekin‐Taner, N., Graff‐Radford, N., Younkin, L. H., Eckman, C., Adamson, J., Schaid, D. J., Blangero, J., Hutton, M., & Younkin, S. G.
- Venue
- Genetic Epidemiology
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 21
- Issue
- 1
- Pages
- 19-30
- ISSN
- 0741-0395 (ISSN-L)
- 1098-2272
- OpenAlex
- W2004690181
- Cited by
- 54
- References
- 11
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.